ISSN 2415-3060 (print), ISSN 2522-4972 (online)
  • 26 of 57
JMBS 2020, 5(1): 179–186
Clinical Medicine

Indicators of Oxidative Stress and Antioxidant Activity in the Comorbidity of Non-Alcoholic Fatty Liver Disease and Arterial Hypertension

Prosolenko K. O.

It is known that oxidative stress is one of the most important pathogenetic mechanisms of cardiovascular diseases. Its role in the development and progression of chronic liver and kidney diseases is also well known. The purpose of the work was to study the state of lipid peroxidation and antioxidant protection in patients with non-alcoholic fatty liver disease and its comorbidity with essential hypertension or renoparenchymal arterial hypertension, as well as assess the main factors affecting antioxidant defense in this category of patients. Material and methods. The object of the study was 269 patients, including 60 patients with non-alcoholic fatty liver disease, 121 patients with comorbidity and essential hypertension, 88 patients with comorbidity and renoparenchymal arterial hypertension. The control group consisted of 20 healthy individuals. Clinical examination of patients included an assessment of the objective examination parameters, in particular, anthropometric data and blood pressure according to standard methods. We used an ultrasonic research method (ultrasound scanner "GE", USA). Blood biochemical parameters were determined according to standard generally accepted methods: ALT, total cholesterol, insulin levels with the determination of the HOMA index, adiponectin levels, tumor necrosis factor-α concentration, glomerular filtration rate according to the CKD-EPI formula. The state of the prooxidant system was evaluated by the levels of diene conjugates and malondialdehyde, and the state of the enzymatic antioxidant defense system was assessed by the activity of superoxidedismutase. Results and discussion. We found a significant increase in both indicators of oxidative stress in all three groups compared to the control group (p <0.001). In addition to an increase in lipid peroxidation, we observed a decrease in superoxidedismutase in the studied patients. It was most significant in the group of comorbidity with renoparenchymal arterial hypertension – 25.15 ± 3.28 U / mg Hb min. The influence of oxidative stress indicators on almost all parameters that were investigated in non-alcoholic fatty liver disease and its comorbidity with arterial hypertension was revealed. Differences were recorded, mainly according to blood pressure, total cholesterol, body mass index and glomerular filtration rate. According to analysis of variance MANOVA, a significant effect of the factor “non-alcoholic fatty liver disease” and the factor “arterial hypertension” on each of the three indicators of the lipid peroxidation system and antioxidant defense (p <0.001) was found. In our opinion, the fact that the indicators of oxidative stress are strongly influenced not only by each factor individually, but also by their interaction is very important. The most powerful effect was found for the indicator of superoxidedismutase - F = 40.9 (p <0.001). Conclusion. Thus, the processes of lipid peroxidation and antioxidant protection are disrupted in patients with non-alcoholic fatty liver disease. Comorbidity with essential hypertension or renoparenchymal arterial hypertension makes these disorders more pronounced, which can affect both the onset and course of these diseases. The spectrum of significant correlation is different between patients with isolated non-alcoholic fatty liver disease and its comorbidity, which may indicate several different pathogenetic mechanisms of the onset and progression of these diseases. When non-alcoholic fatty liver disease with essential hypertension or renoparenchymal arterial hypertension is comorbid, disturbances in lipid peroxidation and antioxidant defense are associated with the mutually beneficial effect of these nosologies.

Keywords: oxidative stress, non-alcoholic fatty liver disease, arterial hypertension

Full text: PDF (Ukr) 218K

  1. Avalueva EB, Lapinskij IV, Bakulin IG i dr. Osobennosti antioksidantnoj sistemy` i polimorfizmov nekotory`kh genov-kandidatov u paczientov s nealkogol`noj zhirovoj bolezn`yu pecheni [Features of the antioxidant system and polymorphisms of certain candidate genes in patients with non-alcoholic fatty liver disease]. Farmateka. 2018; 9(362): 48-55. [Russian]
  2. Ayala A, Muñoz MF, Argüelles S. Lipid Peroxidation: Production, Metabolism, and Signaling Mechanisms of Malondialdehyde and 4-Hydroxy-2-Nonenal. Oxidative Medicine and Cellular Longevity. 2014; 2014. ID 360438.
  3. Belaya IE Markery` okislitel`nogo stressa u paczientov s ostry`m infarktom miokarda s nealkogol`noj zhirovoj bolezn`yu pecheni [The markers of oxidative stress in patients with acute myocardial infarction with non-alcoholic fatty liver disease]. Rossijskij kardiologicheskij zhurnal. 2014; (7): 98-104. [Russian]
  4. Bulatova IA, Schekotova AP, Suzdaltseva KN, i dr. Superoksiddismutaza i glutationperoksidaza pri hronicheskom gepatite C i nealkogolnoy zhirovoy bolezni pecheni [Superoxide dismutase and glutathione peroxidase in chronic hepatitis C and non-alcoholic fatty liver disease]. Fundamentalnyie issledovaniya. 2014; 7(3): 455–9. [Russian]
  5. Khukhli`na OS, Kuzminska OB, Danilishin TM, Grinyuk OYe, Kropiva VV. Rol` oksidativnogo stresu v patogenezi` progresuvannya nealkogol`nogo steatogepatitu za umov komorbi`dnosti` z i`shemi`chnoyu khvoroboyu serczya [The role of oxidative stress in the pathogenesis of progression of non-alcoholic steatohepatitis under conditions of co-morbidity with coronary heart disease]. Visnik Ukrayinskoyi medichnoyi stomatologi`chnoyi akademi`yi. 2018; 4(64): 76-9. [Ukrainian]
  6. Popov SS, Pashkov AN, Shulgin AK i dr. Aktivnost superoksiddismutazy. katalazy i soderzhaniye α-tokoferola v syvorotke krovi bolnykh sakharnym diabetom 2 tipa, oslozhnennym steatogepatitom, pri provedenii kombinirovannogo lecheniya s epifaminom [The activity of superoxide dismutase, catalase and the content of α-tocopherol in the blood serum of patients with type 2 diabetes mellitus, complicated by steatohepatitis, during the combined treatment with epifamin]. Kurskiy nauchno-prakticheskiy sbornik «Chelovek i zdorovye». 2014; 1: 92-7. [Russian]
  7. Promenasheva TE, Kolesnichenko LS, Kozlova NM Rol` oksidativnogo stressa i sistemy` glutationa v patogeneze nealkogol`noj zhirovoj bolezni pecheni [The role of oxidative stress and glutathione in the pathogenesis of non-alcoholic fatty liver disease]. Bulletin RSSC SB RAMS. 2014; 5(99): 80-3. [Russian]
  8. Shalimova AS Vpliv α-li`poyevoyi kisloti na oksidativnij stres u pacziyentiv z gipertonichnoyu khvoroboyu i czukrovim diabetom 2 tipu [Effect of α-lipoic acid on oxidative stress in patients with type 2 hypertension]. Simejna mediczina. 2013; 6(50): 116–9. [Ukrainian]
  9. Weber D, Milkovic L, Bennett SJ, Griffiths HR, Zarkovic N, Grune T. Measurement of HNE-protein adducts in human plasma and serum by ELISA – Comparison of two primary antibodies. Redox Biol. 2013; 1(1): 226–33. PMID: 24024156. PMCID: PMC3757688.
  10. Al-Serri A, Anstee QM, Valenti L, Nobili V, Leathart JB, Dongiovanni P, et al. The SOD2 C47T polymorphism influences NAFLD fibrosis severity: evidence from casecontrol and intra-familial allele association studies. J Hepatol. 2012; 56(2): 448–54. PMID: 21756849.
  11. Targher G, Bertolini L, Rodella S, Lippi G, Zoppini G, Chonchol M. Relationship between kidney function and liver histology in subjects with nonalcoholic steatohepatitis. Clin J Am Soc Nephrol. 2010; 5: 2166–71. PMID: 20724519. PMCID: PMC2994076.